Name: mPEG9-amine
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

m-PEG9-amine; 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-amine; MPEG9-NH2; Methyl-PEG9-amine

IUPAC Name

2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanamine

Canonical SMILES

COCCOCCOCCOCCOCCOCCOCCOCCOCCN

InChI

InChI=1S/C19H41NO9/c1-21-4-5-23-8-9-25-12-13-27-16-17-29-19-18-28-15-14-26-11-10-24-7-6-22-3-2-20/h2-20H2,1H3

InChIKey

FYQAZBUDEOSOFG-UHFFFAOYSA-N

Density

1.060±0.06 g/cm3 (Predicted)

Solubility

Soluble in DMSO (10 mm)

PSA

109.09000

Appearance

Pale Yellow Oily Liquid

Shelf Life

≥ 2 years

Shipping

Room temperature, or blue ice upon request.

Storage

Store at 2-8°C

Boiling Point

484.3±40.0 °C at 760 mmHg

Biological Activity

m-PEG9-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1] . In Vitro: ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.

mPEG9-amine, a versatile polyethylene glycol derivative, is prized for its chemical properties and finds widespread utility in bioconjugation endeavors. Here are four key applications of mPEG9-amine:

Drug Delivery Systems: Delving into the realm of drug delivery, mPEG9-amine emerges as a pivotal player in modifying drug molecules to heighten their solubility, stability, and bioavailability. Through the attachment of polyethylene glycol (PEG) chains to drugs, researchers can mitigate immunogenic responses and extend circulation time in the bloodstream. This innovative PEGylation approach yields enhanced therapeutic outcomes across a spectrum of pharmaceuticals encompassing anticancer agents and biologics.

Bioconjugation: Pioneering advancements in bioconjugation, mPEG9-amine assumes the role of a connector molecule, facilitating the linkage of functional groups or biomolecules to proteins, peptides, or other macromolecules. This transformative modification journey enhances the pharmacokinetic and pharmacodynamic profiles of biologics.

Surface Modification: Venturing into the domain of surface engineering, mPEG9-amine unfurls its potential in enhancing the biocompatibility of nanoparticles, biomaterials, and medical devices while concurrently curtailing non-specific binding events. The PEG chains act as guardians, erecting a protective shield that fends off unwanted protein adhesion and immune responses.

1.HDL functionality in South Asians as compared to white Caucasians.

Bakker LE1, Boon MR2, Annema W3, Dikkers A4, van Eyk HJ1, Verhoeven A5, Mayboroda OA5, Jukema JW6, Havekes LM7, Meinders AE1, Willems van Dijk K8, Jazet IM1, Tietge UJ3, Rensen PC9. Nutr Metab Cardiovasc Dis. 2016 Feb 19. pii: S0939-4753(15)30087-9. doi: 10.1016/j.numecd.2016.02.010. [Epub ahead of print]

BACKGROUND AND AIMS: South Asians have an exceptionally high risk of developing cardiovascular disease compared to white Caucasians. A contributing factor might be dysfunction of high density lipoprotein (HDL). We aimed to compare HDL function in different age groups of both ethnicities.

2.[Treatment of the old terrible triad of the elbow without operative history].

Zha YJ1, Jiang XY1, Gong MQ1. Beijing Da Xue Xue Bao. 2016 Apr 18;48(2):224-9.

OBJECTIVE: To introduce the surgical techniques and treating results of the old "terrible triad" of the elbow.

3.Impact of a systems engineering intervention on PMTCT service delivery in Côte d'Ivoire, Kenya, Mozambique: a cluster randomized trial.

Rustagi AS1, Gimbel S, Nduati R, Cuembelo MF, Wasserheit JN, Farquhar C, Gloyd S, Sherr K; with input from the SAIA Study Team. J Acquir Immune Defic Syndr. 2016 Apr 14. [Epub ahead of print]

BACKGROUND: Efficacious interventions to prevent mother-to-child HIV transmission (PMTCT) have not translated well into effective programs. Prior studies of systems engineering applications to PMTCT lacked comparison groups or randomization.

4.Comparison of mid-term haemodynamic performance between the BioValsalva and the BioIntegral valved conduits after aortic root replacement.

Wendt D1, Raweh A2, Knipp S2, El Gabry M2, Eißmann M3, Dohle DS2, Tsagakis K2, Thielmann M2, Jakob H2, Benedik J2. Interact Cardiovasc Thorac Surg. 2016 Apr 4. pii: ivw066. [Epub ahead of print]

OBJECTIVES: We retrospectively compared the haemodynamic performance of the BioValsalva (BV) and BioIntegral (BI) biological aortic-valved conduits in the aortic root position.

Catalog	Product Name	CAS
BADC-00938	mPEG10-amine	1383658-09-0
BADC-00986	mPEG7-amine	170572-38-0
BADC-01011	mPEG6-amine	184357-46-8
BADC-01648	m-PEG12-amine	1977493-48-3
BADC-01115	mPEG2-amine	31576-51-9
BADC-01149	mPEG3-amine	74654-07-2
BADC-01166	mPEG4-amine	85030-56-4
BADC-01167	mPEG11-amine	854601-60-8
BADC-01177	mPEG8-amine	869718-81-0